114 related articles for article (PubMed ID: 36165021)
1. [Enhanced Natural Killers with CISH and B2M Gene Knockouts Reveal Increased Cytotoxicity in Glioblastoma Primary Cultures].
Yusubalieva GM; Dashinimaev EB; Gorchakov AA; Kulemzin SV; Brovkina OA; Kalinkin AA; Vinokurov AG; Shirmanova MV; Baklaushev VP
Mol Biol (Mosk); 2022; 56(5):848-859. PubMed ID: 36165021
[TBL] [Abstract][Full Text] [Related]
2. VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells.
Smagina AS; Kulemzin SV; Yusubalieva GM; Kedrova AG; Sanzharov AE; Ivanov YV; Matvienko DA; Kalsin VA; Gorchakov AA; Baklaushev VP; Taranin AV
Biotechnol Appl Biochem; 2021 Aug; 68(4):849-855. PubMed ID: 32767384
[TBL] [Abstract][Full Text] [Related]
3. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
4. Impairment in cytotoxicity and expression of NK cell- activating receptors on human NK cells following exposure to asbestos fibers.
Nishimura Y; Miura Y; Maeda M; Kumagai N; Murakami S; Hayashi H; Fukuoka K; Nakano T; Otsuki T
Int J Immunopathol Pharmacol; 2009; 22(3):579-90. PubMed ID: 19822075
[TBL] [Abstract][Full Text] [Related]
5. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
6. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278
[TBL] [Abstract][Full Text] [Related]
7. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
Lin Chua H; Brahmi Z
Cell Immunol; 2002 Sep; 219(1):57-70. PubMed ID: 12473268
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of B7 molecules by the Epstein-Barr virus enhances susceptibility to lysis by a human NK-like cell line.
Montel AH; Morse PA; Brahmi Z
Cell Immunol; 1995 Jan; 160(1):104-14. PubMed ID: 7531116
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells.
Harnack U; Johnen H; Pecher G
Anticancer Res; 2011 Feb; 31(2):475-9. PubMed ID: 21378326
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
11. Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line.
Montel AH; Bochan MR; Goebel WS; Brahmi Z
Cell Immunol; 1995 Oct; 165(2):312-7. PubMed ID: 7553897
[TBL] [Abstract][Full Text] [Related]
12. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
13. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
[TBL] [Abstract][Full Text] [Related]
14. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
[TBL] [Abstract][Full Text] [Related]
15. Decrease in phosphorylation of ERK following decreased expression of NK cell-activating receptors in human NK cell line exposed to asbestos.
Nishimura Y; Maeda M; Kumagai N; Hayashi H; Miura Y; Otsuki T
Int J Immunopathol Pharmacol; 2009; 22(4):879-88. PubMed ID: 20074451
[TBL] [Abstract][Full Text] [Related]
16. CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C.
Teng JM; Liu XR; Mills GB; Dupont B
J Immunol; 1996 May; 156(9):3222-32. PubMed ID: 8617944
[TBL] [Abstract][Full Text] [Related]
17. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
18. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
19. Fas involvement in cytotoxicity mediated by human NK cells.
Montel AH; Bochan MR; Hobbs JA; Lynch DH; Brahmi Z
Cell Immunol; 1995 Dec; 166(2):236-46. PubMed ID: 7497525
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
Zhu H; Blum RH; Bernareggi D; Ask EH; Wu Z; Hoel HJ; Meng Z; Wu C; Guan KL; Malmberg KJ; Kaufman DS
Cell Stem Cell; 2020 Aug; 27(2):224-237.e6. PubMed ID: 32531207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
